1-20 of 757 Search Results for

vegf

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Developments in Ophthalmology
Volume: 55
Published: 27 October 2015
10.1159/000439008
EISBN: 978-3-318-05565-8
... Abstract Vascular endothelial growth factor (VEGF) inhibitors currently used to treat eye diseases have included monoclonal antibodies, antibody fragments, and an aptamer. A different method of achieving VEGF blockade in retinal diseases includes the concept of a cytokine trap. Cytokine traps...
Book
Book Cover Image
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/isbn.978-3-8055-9530-8
EISBN: 978-3-8055-9530-8
Book Chapter
Series: Developments in Ophthalmology
Volume: 44
Published: 19 June 2009
10.1159/000223947
EISBN: 978-3-8055-9030-3
... hyaloid. This review assesses the role of intravitreal application of vascular endothelial growth factor (VEGF)inhibitors in combination with surgical removal of the vitreous. Vitrectomy with removal of the posterior hyaloids wash out the pocket of preretinal growth factors and enhance the diffusion...
Book Chapter
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320017
EISBN: 978-3-8055-9530-8
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320005
EISBN: 978-3-8055-9530-8
... to inhibitors and vice versa. Angiostatic factors can be divided into passive, active, unspecific and specific ones.Some of them act during neovascularization as members of feedback loops by modifying the effects of their angiogenic counterparts. Among the angiogenic factors VEGF is the most...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320006
EISBN: 978-3-8055-9530-8
...-vascular and microvascular cells, such as endothelial cells and pericytes, via several angiogenic growth factors and inhibitors. Of these growth factors, vascular endothelial growth factor (VEGF) has emerged as the single most important causal agent of angiogenesis in health and disease in the eye. During...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320007
EISBN: 978-3-8055-9530-8
.... The introduction of new intravitreally injectable inhibitors of vascular endothelial growth factor (VEGF) revolutionized the management of the wet form. Pegaptanib was the first anti-VEGF agent to be approved by the US Food and Drug Administration (FDA) for use in neovascular AMD. The VISION study showed...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320008
EISBN: 978-3-8055-9530-8
... and, more specifically, the therapy employing antivascular endothelial growth factor (anti-VEGF) drugs could play a meaningful role. VEGF is a pluripotent growth factor that functions as an endothelial cell-specific mitogen and vasopermeability factor. Through these mechanisms VEGF plays a critical role...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320009
EISBN: 978-3-8055-9530-8
.... Until recently, sufficient evidence-based studies were only available for the effect of grid and scatter laser therapy on RVO. New studies have shown a positive effect of intravitreal therapy with vascular endothelial growth factor inhibitors (anti-VEGF therapy) on the progression of the disease...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320010
EISBN: 978-3-8055-9530-8
... by atrophy of the RPE and overlying retina and subsequent vascular endothelial growth factor (VEGF) release [ 4 ]. The risk of developing CNV was, thus, found to be greatest in eyes with patchy atrophy or lacquer cracks [ 4 ]. Intravitreal injections of anti-VEGF molecules, such as bevacizumab...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320011
EISBN: 978-3-8055-9530-8
... histoplasmosis syndrome, Beçhet’s disease, multiple evanescent white dot syndrome, birdshot chorioretinopathy, acute multifocal posterior placoid pigment epitheliopathy, serpiginous choroiditis, and persistent placoid maculopathy. Results that have reported on antivascular endothelial growth factor (anti-VEGF...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320012
EISBN: 978-3-8055-9530-8
... (CNV). This exudative disease of the central retina leads to loss of visual acuity, and results of treatments in the past have been disappointing. From the present evidence it may be concluded that intravitreal antivascular endothelial growth factor (anti-VEGF) therapy with ranibizumab or bevacizumaab...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320013
EISBN: 978-3-8055-9530-8
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320014
EISBN: 978-3-8055-9530-8
... to it: special focus is on diabetic retinopathy, retinal venous occlusions and a number of inflammatory disorders. Currently available data on up-to-date pharmacologic treatment options such as steroids and anti-VEGF compounds is presented and discussed. Broadly defined, macular edema (ME) is an abnormal...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320015
EISBN: 978-3-8055-9530-8
... are angiogenesis-dependent, initiated studies of angiogenesis in tumor biology [ 2 ]. Vascular endothelial growth factor (VEGF) and many other angiogenic proteins were found to play a major role in ocular and general angiogenesis. When a tumor starts to expand, the need for oxygen and nutrients increases...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320016
EISBN: 978-3-8055-9530-8
... Abstract Proangiogenic growth factors, mainly VEGF (vascular endothelial growth factor) play a significant role in anterior segment diseases, characterized by neovascularization. Newly grown vessels in the cornea can lead to an impairment of transparency and visual acuity. Neovascularization...
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320018
EISBN: 978-3-8055-9530-8
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
10.1159/000320019
EISBN: 978-3-8055-9530-8
Book Chapter
Book: Anti-VEGF
Series: Developments in Ophthalmology
Volume: 46
Published: 13 August 2010
EISBN: 978-3-8055-9530-8
... in development and disease. Nature 2005;438:960-966 4. Schlingemann RO, Witmer AN: Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 2009;175:253-267 5. Witmer AN, Vrensen GFJM, van Noorden CJF, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog...